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Abstract 
Aim. – Our study investigated the relationship between both spontaneous and iatrogenic hypoglycaemia and 
mortality. 
 
Methods. – A total of 200,859 patients from the eICU Collaborative Research Database were grouped by 
whether they had registered episodes of hypoglycaemia or not. Patients with hypoglycaemia were then 













Spontaneous hypoglycaemia during an ICU stay was defined as one or more registered blood glucose 
measurements < 70 mg/dL (3.9 mmol/L) with no evidence of insulin therapy. 
 
Results. – Evidence of at least one hypoglycaemic episode during ICU hospitalization was associated with a 
significant increase in mortality: the observed mortality rate in such patients was 15.6% compared with 8% 
in patients without hypoglycaemia (P < 0.001). Multivariate logistic regression analysis was performed with 
APACHE scores, hypoglycaemia and baseline data (age, gender, ethnicity). Spontaneous hypoglycaemia 
remained a statistically significant predictor of mortality with an adjusted odds ratio (OR) of 1.61 (95% CI: 
1.38–1.88; P < 0.001), whereas iatrogenic hypoglycaemia was not a significant predictor with an adjusted 
OR of 0.97 (95% CI: 0.82–1.14; P = 0.71). 
 
Conclusion. – Spontaneous hypoglycaemia observed in ICU patients was associated with increased mortality 
and increased length of ICU stay. Although the present study, given its observational design, cannot provide 
a definitive answer, the clear difference between spontaneous and iatrogenic hypoglycaemia does not support 
a causal relationship between (short-lasting) hypoglycaemia and adverse outcomes, but instead indicates that 
(short-lasting) hypoglycaemia may be a marker of illness severity. 
 














Hyperglycaemia frequently arises in patients treated in intensive care units (ICUs), and is associated with 
high morbidity and mortality [1,2]. However, Van den Berghe et al. [3] demonstrated that intensive insulin 
therapy to maintain blood glucose at < 110 mg/dL (6.1 mmol/L) reduces morbidity and mortality among 
critically ill patients in surgical ICUs. Therefore, for many years, intensive insulin therapy in critically ill 
patients has been recommended to improve patient outcomes [4–6], and newer evidence in relation to sepsis 
has led to recommendations for targeting an upper blood glucose level of ≤ 180 mg/dL rather than ≤ 110 
mg/dL [7]. Nevertheless, insulin therapy increases the risk of hypoglycaemia in these patients, and several 
studies in recent years have indicated that hypoglycaemia may be a possible predictor of morbidity and 
mortality in critically ill ICU patients [3,8–10]. In fact, initial studies have suggested that the association 
between hypoglycaemia and mortality might be related to spontaneous hypoglycaemia as opposed to 
iatrogenic hypoglycaemia, which means that hypoglycaemia could be a biomarker of a poor prognosis rather 
than an actual cause of mortality [3,9,11]. Indeed, the Normoglycemia in Intensive Care Evaluation–Survival 
Using Glucose Algorithm Regulation (NICE–SUGAR) trial demonstrated that, in critically ill patients 
randomly assigned to either intensive or conventional glucose control, the former led to moderate and severe 
hypoglycaemia, both of which are associated with increased mortality [10,12,13]. 
Thus, the incidence of hypoglycaemia appears to be an important component of blood glucose control in 
critically ill patients, even though no causal link between hypoglycaemia and mortality has been established 
[8]. Moreover, studies have mainly focused on ICU patients from a limited number of hospitals/ICU units. 
Our present study therefore sought to investigate the relationship between both spontaneous and iatrogenic 
















The study is based on a post-hoc analysis of the eICU Collaborative Research Database, a large multicentre 
critical-care database made available by Philips Healthcare in partnership with the MIT Laboratory for 
Computational Physiology. The database comprises data from a number of critical care units across the 
continental US and covers patients who were admitted to critical care units in 2014 and 2015. All data were 
stored and retrieved electronically using the Philips Healthcare (Best, Netherlands) eICU programme 
(Telehealth for the ICU). All data were made anonymous prior to research analyses by the eICU programme. 
Documentation of the database is available at www.eicu-crd.mit.edu. As our study was an independent 
research analysis of the already available eICU database, no approval was needed from our local ethics 
committee, although it was reviewed and approved by the review board of PhysioNet. 
All of the patients studied were divided according to whether they had registered episodes of hypoglycaemia 
or not. Patients with hypoglycaemia were also further divided into subgroups according to type of 
hypoglycaemia: spontaneous hypoglycaemia or iatrogenic hypoglycaemia. Spontaneous hypoglycaemia 
during an ICU stay was defined as one or more registered blood glucose measurements < 70 mg/dL (3.9 
mmol/L) and no evidence of insulin therapy, whereas iatrogenic hypoglycaemia was defined as having 
evidence of insulin therapy. Severe hypoglycaemia was defined as registered blood glucose measurements < 
40 mg/dL (2.2 mmol/L).  These divisions and subgroups of patients are illustrated in Fig. 1.  
Three analyses were investigated in this study: (i) one compared all patients according to evidence of 
hypoglycaemia; (ii) another compared the subgroup of patients with spontaneous and iatrogenic 
hypoglycaemia; and (iii) the third compared the subgroup of patients receiving insulin treatment according to 
evidence or no evidence of hypoglycaemia. Each admitted patient was treated independently, although some 
patients in the dataset may have had multiple admissions. 
Mortality was defined as death during ICU admission. Length of admission (LOS) to the ICU was calculated 
as the total time spent in the ICU during hospital admission. Severity of illness was assessed according to the 
Acute Physiology and Chronic Health Evaluation (APACHE) IV classification system during the initial 
transfer to the ICU. All blood glucose measurements were performed with an ICU blood gas analyzer at the 













Evidence from observational and prospective randomized clinical trials (RCTs) in patients with and without 
diabetes, as well as critically ill and non-critically ill patients, has previously shown a link between 
hyperglycaemia and clinical outcomes [15,16]. Hyperglycaemia in hospital affects up to 46% of non-
critically ill hospitalized patients [17]. The results of observational studies and RCTs indicate that 
hyperglycaemia in hospitalized patients with or without diabetes is associated with an increased risk of 
complications, mortality, longer hospital stays and a greater need for home care after hospital discharge [18]. 
Therefore, the central question relates to the risk of hypoglycaemia as a complication of treating 
hyperglycaemia. To assess this issue, the group receiving insulin was divided into patients with evidence of 
hypoglycaemia and patients with no evidence of hypoglycaemia for comparison.  
 
Statistical analyses 
The primary outcome of our investigation was hospital mortality related to hypoglycaemia. Patients with 
hypoglycaemia were separated into survivors and non-survivors. Categorical variables were summarized 
with the use of proportions, and comparisons between groups were conducted using a chi-squared test. 
Continuous variables were summarized using either the mean (standard deviation, SD) or median 
(interquartile range, IQR) as appropriate. Comparisons between groups were assessed with a t test or the 
Wilcoxon rank-sum test as suitable. A P value < 0.05 was considered statistically significant. 
To predict the influence of hypoglycaemia on mortality, multivariate logistic regression models were 
developed using all available demographic variables and possible predictors of mortality (APACHE IV 
scores, hypoglycaemia, age, gender, ethnicity), and stepwise regression. Model calibration was determined 
using the Hosmer–Lemeshow goodness-of-fit test. A generalized linear model (GLM) was used to assess 
LOS in both unadjusted and adjusted analyses (adjusting for baseline characteristics and APACHE scores). 
All analyses were performed using either MATLAB R2016b version 9.1 (MathWorks, Inc., Natick, MA, 
USA) or IBM SPSS version 24 (IBM Corp., Armonk, NY, USA) software. Missing data were assumed to be 













Thus, 10 complete baseline datasets were created. IBM SPSS uses linear regression for continuous variables 
and logistic regression for categorical variables. Imputation models included all baseline variables, but 




A total of 200,859 patients were included in our study. Their average age was 63.4 (17.1) years, their 
APACHE score was 55.1 (26.1), 54.4% were male, and there was a 22.8% prevalence of diabetes. A total 
mortality rate of 8.6% was observed in these patients; the median (25th, 75th percentile) ICU length of stay 
was 1.8 (0.9, 3.3) days and the total hospital length of stay was 5.6 (2.9, 10.1) days. Missing data accounted 
for 7% of all data, with 30% of cases missing one or more data points. Analysis of the missing data did not 
indicate that the data were not MAR. 
 
Hypoglycaemia 
The prevalence of identified hypoglycaemia in the ICU patients studied was 7.9%, equivalent to 15,844 
patients [0.9% with severe hypoglycaemia, defined by glucose levels < 40 mg/dL (2.2 mmol/L)]. A 
comparison of patients with and without hypoglycaemia is presented in Table I. The evidence shows that 
having at least one hypoglycaemic episode during ICU hospitalization was associated with a significant 
increase in mortality: the observed mortality rate in patients with hypoglycaemia was 15.6% compared with 
8% in patients without hypoglycaemia (P < 0.001), and the observed rate in patients with severe 
hypoglycaemia was 27.8%. Also, the length of ICU stay was longer for the group with vs without 
hypoglycaemia, with a median of 2.6 days vs 1.8 days (P < 0.001), respectively. The effect of hypoglycaemia 
on LOS was 1.12 days [95% confidence interval (CI): 1.06–1.18; P < 0.001] in the adjusted analysis and 













hypoglycaemia also had a higher initial calculated APACHE score of 68.5 vs 53.8 in the non-hypoglycaemia 
group (P < 0.001). Moreover, a greater proportion of patients with diabetes was observed in this group. 
Multivariate logistic regression analysis of APACHE scores, observed hypoglycaemia and baseline data 
(age, gender, height, weight, diabetes, ethnicity) revealed that general hypoglycaemia remained a statistically 
significant predictor of mortality, with an adjusted odds ratio (OR) of 1.22 (95% CI: 1.15–1.29; P < 0.001) 
compared with an unadjusted OR of 2.12 (95% CI: 2.02–2.22). Moreover, those with observed severe 
hypoglycaemia (glucose < 40 mg/dL, or 2.2 mmol/L) had an adjusted OR of 2.00 (95% CI: 1.75–2.30; P < 
0.001). These ORs are presented in Table IV. 
 
Spontaneous vs iatrogenic 
Of the 15,844 patients with identified hypoglycaemia, 12,791 patients (81%) had spontaneous 
hypoglycaemia, and 3053 patients (19%) with iatrogenic hypoglycaemia were registered as having been 
given insulin (Table II). Both groups had higher incidences of mortality compared with the group without 
hypoglycaemia: mortality rates were 15.6% in patients with spontaneous hypoglycaemia and 11.5% in those 
with iatrogenic hypoglycaemia vs 8% in patients without hypoglycaemia (P < 0.001). The difference in 
mortality rates was also significant between the two hypoglycaemic groups (P < 0.001). In addition, both 
hypoglycaemic groups had greater lengths of ICU stays compared with the group without hypoglycaemia: 
the average length of ICU stay was 2.6 days for spontaneous hypoglycaemia and 2.7 days for iatrogenic 
hypoglycaemia. Furthermore, the effect of spontaneous hypoglycaemia on LOS was not significant in either 
the adjusted or unadjusted analysis. 
Not surprisingly, the iatrogenic hypoglycaemia group had a greater prevalence of patients with diabetes, 
57.8% compared with 30.1% for spontaneous hypoglycaemia. There was also a greater proportion of Asians, 
African Americans and Hispanics in the iatrogenic hypoglycaemia group, which could have been related to 













Multivariate logistic regression analysis of APACHE scores, hypoglycaemia type and baseline data (age, 
gender, height, weight, diabetes, ethnicity) showed that the type of hypoglycaemia remained a statistically 
significant predictor of mortality: for spontaneous hypoglycaemia, the adjusted OR was 1.61 (95% CI: 1.38–
1.88; P < 0.001) vs the unadjusted OR of 1.54 (95% CI: 1.36–1.73). 
 
Insulin treatment 
Of the 200,859 patients studied, 26,430 (13.2%) received insulin therapy during ICU admission. In this 
group of patients, the incidence of at least one case of hypoglycaemia was 13.1%, which was equivalent to 
the percentage of the 3053 patients with iatrogenic hypoglycaemia (and the 23,377 without hypoglycaemia; 
Table III). In this subgroup, 1904 had diabetes, and the mortality rate for these patients was 5.7%. 
APACHE scores differed between groups: 58.8 for non-hypoglycaemia patients; and 66.2 for iatrogenic 
hypoglycaemia patients (P < 0.001). In addition, mortality and length of ICU stay were also different 
between these groups: the mortality rate was 8.7% and median length of ICU stay was 2 days for non-
hypoglycaemia patients vs 11.5% and 2.7 days, respectively, for hypoglycaemia patients (P < 0.001). The 
effect of having observed hypoglycaemia (vs no hypoglycaemia) on LOS in this group was 1.02 days (0.85–
1.19; P < 0.001) in the adjusted analysis and 1.23 days (1.06–1.40; P < 0.001) in the unadjusted analysis. 
Multivariate logistic regression analyses of the APACHE scores, observed hypoglycaemia and baseline data 
(age, gender, height, weight, diabetes, ethnicity) revealed that having hypoglycaemia was not a statistically 
significant predictor of mortality (P = 0.71), with an adjusted OR of 0.97 (95% CI: 0.82–1.14) compared 
with an unadjusted OR of 1.42 (95% CI: 1.26–1.61).  
 
Discussion  
Our present study aimed to investigate the relationship between hypoglycaemia and adverse events in a 













blood glucose reading < 70 mg/dL (3.9 mmol/L). In general, hypoglycaemia was associated with increases in 
both incidence of mortality and length of ICU stay, an association that remained statistically significant even 
after adjusting for APACHE scores and baseline data. These findings are similar to those of a study by Egi et 
al. [8], who found an association between mild or moderate hypoglycaemia and mortality in 4946 patients 
from two teaching hospitals in Melbourne and Sydney, Australia. Egi et al. also found that the association 
persisted even after adjusting for insulin therapy.  
Questions have been raised regarding the association between iatrogenic hypoglycaemia and mortality. The 
conceptual model suggests that spontaneous hypoglycaemia may be a biomarker of a poor prognosis or an 
underlying disease such as severe infection [19,20] rather than a direct causal relationship. This might imply 
that insulin therapy, in general, is not a risk factor for mortality, even though the risk of hypoglycaemia is 
increased [11]. As an interesting finding in relation to this, it was observed that patients with diabetes and 
iatrogenic hypoglycaemia had lower mortality rates than patients without diabetes. Van den Berghe et al. [3] 
showed that intensive insulin therapy to maintain blood glucose at ≤ 110 mg/dL (6.1 mmol/L) reduced 
morbidity and mortality among critically ill patients. However, the NICE–SUGAR trial found that patients 
randomized to intensive glucose control had higher rates of mortality, although that study still concluded that 
the data was not proof of a causal relationship.  
The results of our present study likewise show that patients who experience iatrogenic hypoglycaemia also 
have a higher rate of mortality than patients without hypoglycaemia and patients receiving insulin therapy 
without hypoglycaemia. Nevertheless, on assessing the subpopulation receiving insulin therapy, this 
association was no longer present after adjusting for APACHE scores and baseline data. Therefore, our 
present results cannot support the hypothesis that insulin treatment is associated with increased mortality 
among ICU patients. Moreover, these results are in line with previous findings by Boucai et al. [21], who 
reported that drug-associated hypoglycaemia was not associated with any increased mortality risk in patients 














Strengths and limitations 
This study has several strengths, including a population size of more than 200,000 patients from a 
multicentre critical-care database. Also, the data were collected systematically and stored in electronic form. 
To our knowledge, the scale of the database makes our study of hypoglycaemia in ICU patients one of the 
most comprehensive thus far. 
Nevertheless, our study also has several important limitations. Although our findings suggest that 
hypoglycaemia is a marker of illness severity rather than being causally related to outcome, a causal 
relationship cannot be ruled out, given the observational nature of the study. Moreover, the lack of an 
association between iatrogenic hypoglycaemia and mortality after adjusting for covariates in the 
subpopulation of patients receiving insulin therapy could potentially be subject to selection bias. However, 
our study used multivariate logistic regression, which is a means to account for some of the potential biases 
associated with observational studies.  
Another potential limitation is the definition of hypoglycaemia. All patients with an observed glucose level < 
70 mg/dL (3.9 mmol/L) were included in the hypoglycaemic group, yielding a high positive predictive rate, 
yet misclassification cannot be ruled out, as glucose measurements were taken by local procedures and 
therefore open to selection bias. Indeed, this is a limitation of all observational studies related to 
investigating hypoglycaemia.  
It is also known that the amount of time spent in hypoglycaemia, and its severity, can profoundly influence 
patients’ outcomes. As observed in our study, the mortality rate among patients with severe hypoglycaemia 
was considerably higher, thereby sparking a discussion on what level of glucose should be used to define 
(relevant) hypoglycaemia in the ICU. However, our study lacked data on the amount of time patients spent in 
the hypoglycaemic zone. Also, the definition of iatrogenic hypoglycaemia was based on evidence of insulin 
therapy in combination with hypoglycaemia, whereas it cannot be known with certainty whether every 
hypoglycaemia was caused by insulin. Finally, as the aim of our study was focused on hypoglycaemia as a 















Even though several studies have investigated the relationship between hypoglycaemia and outcome, many 
questions still remain. It is not clear why the results of different studies are conflicting, especially those 
concerning the use of insulin treatment in critically ill patients. Also, why is hypoglycaemia associated with 
morbidity and mortality in hospitalized patients at all? While previous work has demonstrated a link between 
infections, mortality and observations of hypoglycaemia in ICU patients [19,20], the effect of infections was 
not included in the present study. However, this should be addressed in future studies to adjust for its 
possible effect on hypoglycaemia and outcomes.  
In addition to future studies focusing on the underlying effects of hypoglycaemia on patient outcomes, 
studies are also needed to assess the cost–benefit relationship of reducing hyperglycaemia in the face of an 
increased risk of hypoglycaemia. Another important aspect to investigate in further detail is the impact of 
time spent in hypoglycaemia and the severity of hypoglycaemia in relation to patient outcomes. Finally, it 
may be that a universal glycaemic target for ICU patients is not optimal, as patients’ age, underlying disease 
(such as diabetes), hospital procedures, other medical treatment and general health status have the potential 
to improve their overall treatment and prognoses. 
 
Conclusion  
Our study has found that the spontaneous hypoglycaemia observed in ICU patients is associated with 
increased mortality and longer ICU stays. Also, although our study cannot offer any definitive answers, 
given its observational design, the clear difference between spontaneous and iatrogenic hypoglycaemias does 
not support a causal relationship between (short-lasting) hypoglycaemia and adverse outcomes. Instead, our 
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Figure legend  
 
Fig. 1. Distribution of patients according to evidence of hypoglycaemia and insulin treatment during 


















Patient groups according to evidence or not of hypoglycaemia during stays in the intensive care unit (ICU)  
 
Parameter Hypoglycaemia No 
hypoglycaemia 
Patients, n 15,844 185,015 
APACHE score 68.5 (29.8) 53.8 (25.3)* 
Mortality, % 15.6 8* 
Age, years 63.2 (17) 63.4 (17.1)* 
Gender, male % 48.8 54.4* 
Height, cm 167.5 (13.8) 169.4 (13.5)* 
Weight, kg 79.2 (26) 84.6 (26.9)* 
Diabetes, % 35.7 22.8* 
Ethnicity, %   
Asian 1.8 1.3* 
Caucasian 69.2 78.1* 
African American 17.6 10.4* 
Native American 1.1 1 
Hispanic 4.3 3.5* 
ICU length of stay, daysa 2.6 (1, 5) 1.8 (1, 3)* 
 
Data are presented as means (standard deviation) unless stated as otherwise; * P < 0.05 between groups; a 
median (25th, 75th percentile); 























Patients, n 12,791 3053 
APACHE score 69.1 (30.4) 66.2 (27.6)* 
Mortality, % 16.6 11.5* 
Age, years 63.5 (17) 61.9 (17.1)* 
Gender, male % 48.9 48.7 
Height, cm 167.6 (13.6) 167.3 (14.7) 
Weight, kg 79 (26.1) 79.9 (25.8) 
Diabetes, % 30.1 57.8* 
Ethnicity, %   
Asian 1.6 2.3* 
Caucasian 71.2 60.7* 
African American 16.4 23* 
Native American 1.2 0.9 
Hispanic 3.5 7.5* 
ICU length of stay, daysa 2.6 (1, 5) 2.7 (1, 5) 
 
Data are presented as means (standard deviation) unless stated as otherwise; * P < 0.05 between groups; a 
median (25th, 75th percentile); 


















Patients receiving insulin treatment during intensive care unit (ICU) stays according to evidence or not of 
hypoglycaemia 
 
Parameter Insulin treatment 
 No hypoglycaemia Iatrogenic hypoglycaemia 
Patients, n 23,377 3053 
APACHE score 58.8 (25.9) 66.2 (27.6)* 
Mortality, % 8.7 11.5* 
Age, years 62 (16.9) 61.9 (17.1) 
Gender, male % 54.6 48.7* 
Height, cm 169.4 (15.2) 167.3 (14.7)* 
Weight, kg 86.4 (26.5) 79.9 (25.8)* 
Diabetes, % 50.9 57.8* 
Ethnicity, %   
Asian 1.7 2.3* 
Caucasian 67.4 60.7* 
African American 17.1 23* 
Native American 0.7 0.9 
Hispanic 7.5 7.5 
ICU length of stay, days a 2 (1, 4) 2.7 (1, 5)* 
 
Data are presented as means (standard deviation) unless stated as otherwise; * P < 0.05 between groups; a 
median (25th, 75th percentile); 

















Adjusted and unadjusted odds ratios (95% confidence interval) for mortality in all study groups 
 
Groups Odds ratios 
 Adjusted Unadjusted 
Hypoglycaemia  1.22 (1.15–1.29)** 2.12 (2.02–2.22)** 
Severe hypoglycaemia 2.00 (1.75–2.30)** 4.07 (3.67–4.52)** 
Spontaneous vs iatrogenic 1.61 (1.38–1.88)** 1.54 (1.36–1.73)** 
Insulin treatment 0.97 (0.82–1.14) 1.42 (1.26–1.61)** 
 
* P < 0.05, ** P < 0.001 (between groups) 
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